2 news items
Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
QNCX
13 May 24
for EryDex as corticosteroids are the standard of care for this rare disease, but its utility is limited by significant chronic toxicity due to adrenal
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
QNCX
13 May 24
utility is limited by significant chronic toxicity due to adrenal suppression. We believe EryDex has the potential to provide the therapeutic benefit
- Prev
- 1
- Next